Six versus twelve months of hormone therapy for intermediate-risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial compares 6 versus 12 months of hormone therapy for men with intermediate-risk prostate cancer that hasn't spread. It aims to see if shorter treatment works just as well with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have prostate cancer with a Gleason score of 7, PSA 10-20, or a tumor that can be felt, and at least one other risk factor.
- Cancer has not spread to bones or lymph nodes (confirmed by scans).
- Have not had chemotherapy or surgery for prostate cancer (except a biopsy).
- Are well enough for daily activities (performance status 0 or 1).
- No bilateral hip replacements.
- If you've started hormone therapy, it must have been within the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether giving a shorter-course radiation plan after prostate surgery, along with hormone shots (LHRH), can improve outcomes for people with higher-risk prostate cancer. You may be eligible if your PSA (a blood marker) is either still low but high-risk by pathology, or it has started to rise again after surgery.
This trial tests whether a shorter course of hormone therapy (2 years) plus a new hormone drug (6 months) with radiation is as effective as longer treatment for high-risk prostate cancer that hasn't spread.
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
This trial compares giving radiation in 2 treatments versus 5 treatments for prostate cancer that hasn't spread. It's for men with low or intermediate risk prostate cancer who are healthy enough to undergo a short course of targeted radiation.
This trial studies a more sped-up radiation schedule for men with certain local prostate cancers, given together with hormone therapy. It aims to keep cancer control while possibly reducing treatment time and making care easier.
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.